Liquidity and financing dependence
The business needs external funding and revenue growth to support operations and obligations
- Scope
- Company-wide
- Materiality
- high
Precipio, Inc.
Precipio, Inc. is a U.S.-based healthcare biotechnology company focused on cancer diagnostics. It develops and commercializes diagnostic products and pathology services through its clinical laboratory operations and product division.
0,2 %
44,5 %
−1,5 %
+29,8 %
1.61
1.36
| % | |
|---|---|
| Pathology services | 89% Clinical laboratory testing and diagnostic pathology services performed through the New Haven CLIA lab. |
| Diagnostic products | 11% Cancer-focused laboratory products sold directly and through distributors. |
Precipio sells to laboratories, pathology practices, and healthcare organizations that need cancer diagnostic testing...
- Clinical laboratoriesprimary
Buy diagnostic products and consumables for use in laboratory workflows and testing
- Pathology practices and providersprimary
Use pathology services for cancer-related diagnostic interpretation and testing
- Healthcare distributorssecondary
Purchase and distribute products to reach laboratory customers nationwide
- Patients and referring physicianssecondary
Receive pathology services through the company’s clinical laboratory operations
Precipio is based in the United States and operates primarily through its New Haven, Connecticut clinical laboratory...
- •Headquartered and operating in the United States
- •New Haven CLIA laboratory is a core operating site
- •Primary commercial focus is the U.S. laboratory market
- •Products may be sold internationally through distributors
Precipio’s strategy is built around using its own clinical laboratory as a development and validation engine for new...
01
Use the clinical lab as a product development platformshort-term
Internal testing and validation reduce development time and improve product fit for real workflows
02
Expand distributor-led product commercializationmedium-term
National distributors extend reach into laboratory customers without building a large direct sales footprint
03
Build cancer diagnostics offerings that address misdiagnosislong-term
The company’s product pipeline is centered on solving diagnostic accuracy problems in oncology
Precipio faces execution risk from dependence on reimbursement, billing operations, and access to capital, which are...
Billing and reimbursement disruption
Pathology services depend on third-party billing systems and payer remittances, so interruptions can delay cash collection
- Scope
- Pathology services
- Materiality
- high
Regulatory and reimbursement risk
Clinical laboratory and diagnostic businesses are sensitive to healthcare regulation and payer policy
- Scope
- U.S. diagnostics and pathology
- Materiality
- high
Trade and tariff exposure
Imported goods or supplier inputs may become more expensive under tariff changes
- Scope
- Laboratory products supply chain
- Materiality
- medium
Product development and validation risk
New diagnostics require specimens, skilled staff, and successful validation before commercialization
- Scope
- Pipeline products
- Materiality
- medium
Revenue recognition and reimbursement adjustments
Affects quarterly service revenue and receivables
Allowance for credit losses
Affects reported net sales
Going concern and liquidity assumptions
Affects financial statement presentation and risk disclosure
Billing-related liabilities and recoveries
Affects other liabilities and cash flow
Presidio Property Trust, Inc.
SQFT · Real Estate Investment Trusts
Presidio MidCo Inc.
Blank Checks
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
PRECIGEN, INC.
PGEN · Pharmaceutical Preparations
Innventure, Inc.
INV · Blank Checks
nCino, Inc.
NCNO · Services-Prepackaged Software
: 29.4.2026